

# QUARTERLY

# PCPA UPDATE Q1 2022

January - March 2022

A high-level summary of the quarterly pan-Canadian Pharmaceutical Alliance (pCPA) activity & processes

## pCPA ACTIVITY



**Initiated 26 files**  
(Q4 2021: 23 files)



**Completed 19 files**  
(Q4 2021: 17 files)




**Closed 1 file**  
(Q4 2021: 1 file)



**Declined 0 file**  
(Q4 2021: 1 file)


## FILES UNDER CONSIDERATION



### Insights

- CADTH issued 16 conditional recommendations and 6 'Do Not Reimburse' recommendations in Q1 2022.
- Despite a busy quarter with 26 files being initiated by pCPA, the volume of files under consideration is still high sitting at 33 as of March 2022.
- Meanwhile, the average days under consideration reached 170 days, a decrease from the previous quarter.
- the days under consideration has remained relatively stable over the past 4 quarters hovering between 150-185 days.

## FILES UNDER NEGOTIATION




### Insights


- pCPA initiated a higher number of files (26) than it completed (19) or closed (1) in Q1 2022, resulting in more files under active negotiation in the quarter than any quarter of 2021.
- pCPA had almost twice as many non-oncology files than oncology files under active negotiation by the end of the quarter.
- The average time under negotiation decreased over the quarter, but remains in line with the average timelines seen throughout 2021.

## pCPA CAPACITY

### Volume of Processed Files



### Long Term Files



### Insights

- pCPA completed 2 more negotiations with LOIs in Q1 2022 (19) than Q4 2021 (17), but fewer than Q3 2021 (23). 1 file was closed without reaching an agreement.
- The number of files under consideration for 6 months or more increased to 9 over the quarter, then decreased to 7 in March. This was due to several of the long-term files initiating negotiations in March.
- Meanwhile, the number of files under active negotiation for 12 months or more increased from 1 at the end of 2021 to 3 by the end of Q1 2022.

